X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1365) 1365
fibrinolytic agents - therapeutic use (848) 848
index medicus (791) 791
male (687) 687
female (648) 648
animals (466) 466
middle aged (406) 406
aged (386) 386
fibrinolytic agents - pharmacology (314) 314
hematology (292) 292
adult (282) 282
treatment outcome (281) 281
thrombosis (266) 266
fibrinolytic agents - administration & dosage (257) 257
stroke (233) 233
peripheral vascular disease (221) 221
fibrinolytic agents - adverse effects (218) 218
risk factors (214) 214
cardiac & cardiovascular systems (208) 208
mortality (193) 193
immunology (192) 192
thrombolytic therapy (192) 192
heart attacks (180) 180
time factors (179) 179
anticoagulants (177) 177
aged, 80 and over (164) 164
anticoagulants - therapeutic use (162) 162
therapy (152) 152
tissue plasminogen activator - therapeutic use (150) 150
drug therapy (149) 149
surgery (143) 143
thrombolysis (142) 142
mice (139) 139
retrospective studies (136) 136
care and treatment (133) 133
aspirin (128) 128
medicine, general & internal (124) 124
analysis (123) 123
ischemia (121) 121
patients (121) 121
internal medicine (120) 120
abridged index medicus (115) 115
health aspects (114) 114
rats (113) 113
thromboembolism (112) 112
heparin (110) 110
risk (110) 110
stroke - drug therapy (110) 110
medicine (103) 103
thrombosis - drug therapy (103) 103
fibrinolysis (102) 102
pharmacology & pharmacy (100) 100
fibrinolytic agents - immunology (98) 98
medicine & public health (98) 98
multidisciplinary sciences (97) 97
recombinant proteins - therapeutic use (97) 97
transplantation (95) 95
cardiology (94) 94
myocardial infarction - drug therapy (94) 94
aspirin - therapeutic use (93) 93
heparin - therapeutic use (92) 92
management (90) 90
thrombolytic therapy - methods (90) 90
thrombosis - prevention & control (90) 90
platelet aggregation inhibitors - therapeutic use (89) 89
prevention (89) 89
hemorrhage (88) 88
thrombosis - etiology (87) 87
research article (86) 86
disease models, animal (84) 84
emergency medicine (84) 84
tissue plasminogen activator (82) 82
acute myocardial-infarction (81) 81
inflammation (79) 79
pregnancy (78) 78
prospective studies (78) 78
drug therapy, combination (77) 77
molecular-weight heparin (77) 77
dose-response relationship, drug (75) 75
fibrinolytic agents (75) 75
science (75) 75
studies (74) 74
blood coagulation - drug effects (73) 73
hemorrhage - chemically induced (73) 73
coagulation (71) 71
fibrin (71) 71
heparin - adverse effects (70) 70
research (69) 69
risk assessment (69) 69
cardiovascular disease (68) 68
tissue-plasminogen activator (68) 68
clinical trials (67) 67
emergency (67) 67
hospitals (67) 67
warfarin (67) 67
oncology (66) 66
trial (65) 65
adolescent (63) 63
anticoagulants - adverse effects (63) 63
follow-up studies (63) 63
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1579) 1579
German (10) 10
French (9) 9
Japanese (9) 9
Russian (8) 8
Chinese (7) 7
Spanish (6) 6
Polish (5) 5
Italian (3) 3
Czech (1) 1
Hebrew (1) 1
Hungarian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 05/2008, Volume 99, Issue 5, pp. 830 - 839
Bivalirudin is a direct thrombin inhibitor (DTI) frequently used for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary... 
Direct thrombin inhibitors | Bivalirudin | direct antithrombin agents | Theme Issue Article | Direct antithrombin agents | HEPARIN-INDUCED THROMBOCYTOPENIA | CARDIOPULMONARY BYPASS | CORONARY-ARTERY-BYPASS | POSTINFARCTION ANGINA | ANTICOAGULATION | GLYCOPROTEIN IIB/IIIA BLOCKADE | REPLACE-2 RANDOMIZED-TRIAL | CARDIAC-SURGERY | PERIPHERAL VASCULAR DISEASE | ACUITY TRIAL | HEMATOLOGY | direct thrombin inhibitors | Recombinant Proteins - therapeutic use | Fibrinolytic Agents - chemistry | Hirudins - chemistry | Humans | Acute Coronary Syndrome - mortality | Molecular Sequence Data | Recombinant Proteins - adverse effects | Heparin - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Fibrinolytic Agents - adverse effects | Cardiac Surgical Procedures | Thrombocytopenia - drug therapy | Anticoagulants - chemistry | Fibrinolytic Agents - therapeutic use | Peptide Fragments - immunology | Thrombosis - blood | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Hirudins - immunology | Amino Acid Sequence | Recombinant Proteins - chemistry | Anticoagulants - therapeutic use | Thrombocytopenia - chemically induced | Anticoagulants - adverse effects | Fibrinolytic Agents - immunology | Acute Coronary Syndrome - blood | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Peptide Fragments - chemistry | Animals | Anticoagulants - immunology | Blood Coagulation - drug effects | Recombinant Proteins - immunology | Thrombosis - etiology | Hirudins - adverse effects | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Hemostasis, Surgical - methods | Index Medicus
Journal Article
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 05/2008, Volume 99, Issue 5, pp. 819 - 829
This review discusses the pharmacology and clinical applications of hirudin, a bivalent direct thrombin inhibitor (DTI). Besides the current major indication... 
Deep vein thrombosis | HIT | thrombin | hirudin | Theme Issue Article | Thrombin | Hirudin | ECARIN CLOTTING TIME | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | CARDIOPULMONARY BYPASS | SUBCUTANEOUS RECOMBINANT HIRUDIN | QUANTITATIVE-DETERMINATION | deep vein thrombosis | R-HIRUDIN | ANTIHIRUDIN ANTIBODIES | PERIPHERAL VASCULAR DISEASE | HYPERSENSITIVITY REACTIONS | AORTIC-VALVE-REPLACEMENT | HEMATOLOGY | Anticoagulants - administration & dosage | Humans | Thrombin - antagonists & inhibitors | Heparin - adverse effects | Hirudins - administration & dosage | Hirudin Therapy | Angioplasty, Balloon, Coronary - adverse effects | Fibrinolytic Agents - adverse effects | Thrombocytopenia - drug therapy | Fibrinolytic Agents - pharmacokinetics | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Prothrombin - metabolism | Hirudins - immunology | Hirudins - pharmacokinetics | Anticoagulants - therapeutic use | Thrombocytopenia - chemically induced | Cardiopulmonary Bypass | Anticoagulants - adverse effects | Fibrinolytic Agents - immunology | Thrombocytopenia - blood | Acute Coronary Syndrome - drug therapy | Animals | Anticoagulants - immunology | Blood Coagulation - drug effects | Thrombosis - etiology | Hirudins - adverse effects | Blood Coagulation Tests | Acute Coronary Syndrome - therapy | Vascular Surgical Procedures | Anticoagulants - pharmacokinetics | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Hemorrhage - chemically induced | Thrombin - metabolism | Drug Monitoring | Hemostasis, Surgical - methods | Renal Dialysis | Index Medicus
Journal Article
Seminars in Thrombosis and Hemostasis, ISSN 0094-6176, 12/2005, Volume 31, Issue 6, pp. 681 - 690
ABSTRACT Drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP/HUS) has been recognized for several years. The most commonly... 
Thrombotic microangiopathy | Thrombotic thrombocytopenic purpura | Hemolytic uremic syndrome | Drug toxicity | HEMOLYTIC-UREMIC SYNDROME | BONE-MARROW-TRANSPLANTATION | MITOMYCIN-C | thrombotic thrombocytopenic purpura | VON-WILLEBRAND-FACTOR | hemolytic uremic syndrome | FACTOR-CLEAVING PROTEASE | RENAL-ALLOGRAFTS | INDUCED IMMUNE THROMBOCYTOPENIA | CYCLOSPORINE-A | drug toxicity | PERIPHERAL VASCULAR DISEASE | thrombotic microangiopathy | OF-THE-LITERATURE | HEMATOLOGY | INTERFERON THERAPY | ADAM Proteins - immunology | Endothelium, Vascular - injuries | Humans | Mitomycin - immunology | Antibiotics, Antineoplastic - adverse effects | Hemolytic-Uremic Syndrome - pathology | Fibrinolytic Agents - adverse effects | Quinine - adverse effects | Antibiotics, Antineoplastic - immunology | Ticlopidine - adverse effects | Hemolytic-Uremic Syndrome - therapy | Endothelium, Vascular - immunology | Mitomycin - adverse effects | Ticlopidine - immunology | Hemolytic-Uremic Syndrome - chemically induced | Treatment Outcome | Hemolytic-Uremic Syndrome - immunology | ADAMTS13 Protein | Fibrinolytic Agents - immunology | Purpura, Thrombotic Thrombocytopenic - chemically induced | Quinine - immunology | Purpura, Thrombotic Thrombocytopenic - pathology | Immunosuppressive Agents - immunology | Cyclosporine - adverse effects | Cyclosporine - immunology | Purpura, Thrombotic Thrombocytopenic - immunology | Endothelium, Vascular - pathology | Immunosuppressive Agents - adverse effects | Purpura, Thrombotic Thrombocytopenic - therapy
Journal Article
Critical Care Medicine, ISSN 0090-3493, 07/2001, Volume 29, Issue 7 Suppl 1, pp. S53 - S60
Journal Article
Journal of Liposome Research, ISSN 0898-2104, 2008, Volume 18, Issue 2, pp. 95 - 112
Journal Article
Journal of thrombosis and haemostasis : JTH, 11/2017, Volume 15, Issue 11, p. 2230
Journal Article
Thrombosis Research, ISSN 0049-3848, 2011, Volume 128, Issue 4, pp. 361 - 367
Journal Article
Journal of Cardiovascular Pharmacology and Therapeutics, ISSN 1074-2484, 7/2016, Volume 21, Issue 4, pp. 372 - 380
Background: Thrombolysis is an effective treatment strategy for prosthetic valve thrombosis (PVT). Recombinant tissue-type plasminogen activator (rt-PA) is... 
Heart valve prosthesis | Echocardiography | Tissue plasminogen activator | Thrombosis | Thrombolytic therapy | heart valve prosthesis | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | tissue plasminogen activator | SYSTEMIC LUPUS-ERYTHEMATOSUS | echocardiography | GUIDELINES | T-PA | ANTIPHOSPHOLIPID SYNDROME | thrombosis | RECOMMENDATIONS | DISEASE | thrombolytic therapy | PHARMACOLOGY & PHARMACY | INHIBITOR | Recurrence | Heart Valve Prosthesis Implantation - instrumentation | Prospective Studies | Immunoglobulin G - blood | Humans | Middle Aged | Male | Case-Control Studies | Tissue Plasminogen Activator - adverse effects | Young Adult | Fibrinolytic Agents - adverse effects | Tissue Plasminogen Activator - immunology | Time Factors | Thrombolytic Therapy - methods | Adult | Female | Heart Valve Diseases - diagnosis | Heart Valve Prosthesis | Risk Factors | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Biomarkers - blood | Heart Valve Diseases - etiology | Fibrinolytic Agents - immunology | Pilot Projects | Immunoglobulin M - blood | Heart Valve Prosthesis Implantation - adverse effects | Thrombosis - etiology | Antibodies - blood | Aged | Fibrinolytic Agents - administration & dosage | Heart Valve Diseases - drug therapy | Thrombosis - drug therapy | Thrombolytic Therapy - adverse effects | Thrombosis - diagnosis | Cohort analysis | Usage | Care and treatment | Dosage and administration | Thrombolytic drugs
Journal Article